Navigation Links
Debiopharm Announces U.S. NDA Filing of Trelstar(R) 6-Month Formulation for Locally Advanced or Metastatic Prostate Cancer

LAUSANNE, Switzerland, Nov. 13 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced that the New Drug Application (NDA) for the 6 month formulation of Trelstar(R) (triptorelin pamoate) has been accepted for filing by the United States (U.S.) Food and Drug Administration (FDA). Trelstar(R) is a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of locally advanced or metastatic prostate cancer. Once approved, Trelstar(R) will be commercialised in the U.S. by Watson Pharmaceuticals, Inc.

"Last September we announced the filing of the product with the European Agencies, under the name Decapeptyl(R). We are proud to have accomplished the simultaneous filings of Trelstar(R) and Decapeptyl(R) in both the U.S. and Europe, it's a great achievement for us," said Rolland-Yves Mauvernay, president and founder of Debiopharm Group. "This demonstrates our ability to work effectively not only with different regulatory agencies, but also different partners. Furthermore, our FDA inspected research development and production facility, Debio R.P., will produce both products for global distribution."

The NDA for the 6 month formulation of Trelstar(R) is supported by data from a phase III study on the efficacy and safety of two consecutive injections of triptorelin 6-month formulation in 120 patients with advanced prostate cancer. The results showed that 97.5% of patients achieved castrate levels of serum testosterone 28 days after the first injection and that 93% of the patients maintained serum testosterone levels below castrate level (defined as < 1.735 nmol/L or 50 ng/dL) from week 8 to 48. These efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month formulations of Trelstar(R), which are already marketed by Watson Pharmaceuticals, Inc.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit:

Debiopharm S.A. Contacts Additional Media Contacts

In London

Maurice Wagner Maitland

Director Corporate Affairs & Brian Hudspith

Communications Tel: +44 (0)20 7379 5151

Tel.: +41 (0)21 321 01 11

Fax : +41 (0)21 321 01 69

Jo-Anne Lutjens In New York

Communications Manager Russo Partners, LLC

Tel.: +41 (0)79 370 27 15 Wendy Lau

Fax: +41 (0)21 321 01 69 Tel: +1 212-845-4272 Fax: +1 212-845-4260

SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
2. Ipsen and Debiopharm Extend Their Agreement for the Exclusive Commercialization of Decapeptyl(R) (triptorelin pamoate) in Europe and Certain Other Territories
3. In a Down Economy, Womens Health Company Announces Growth
4. R&Q Solutions, LLC Announces Launch to Serve Regions Medical Device Industry
5. WellPoint Announces Second Annual Innovation Event
6. CVS Caremark All Kids Can Announces the Opening of a Boundless Playground in Los Angeles to Serve Children of All Abilities
7. Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform
8. HealthCentral Announces New Condition-Specific Ad Service to Offer Marketers the Highest Qualified Audiences
9. Wound Management Technologies, Inc. Announces FDA Clearance of 510k
10. GLEH LA, a Nonprofit Affiliate of Gay & Lesbian Elder Housing, Announces New Program Director
11. Governor Rendell Announces the Passing of Lt. Gov. Catherine Baker Knoll
Post Your Comments:
(Date:10/10/2015)... ... 2015 , ... Story Chaser is a one-of-a-kind app that makes ... and inspiring stories and as words drop down and users tap the corresponding word. ... and can be interacted with, making it a more engaging game. Users can use ...
(Date:10/9/2015)... ... ... Doctors on Liens has teamed up with a renowned medical practice, ... to personal injury victims. When personal injury victims suffer major, complex injuries, they ... of conditions ailing them. With the addition of this new group of doctors ...
(Date:10/9/2015)... ... ... A new health tool that helps identify if a sore throat is ... – just in time for the cold and flu season, which the Center for ... the U.S., the real start of cold/flu season is the start of the school ...
(Date:10/9/2015)... ... 2015 , ... Head Over Heels Athletic Arts gymnast, Madelyn Williams, will attend ... Ranch in Huntsville, Texas on October 17-21. , "It's very exciting to be ... and executive director, said. “It's a stepping stone into the U.S. elite system where ...
(Date:10/9/2015)... Orleans, LA (PRWEB) , ... October 09, 2015 ... ... with offices serving New Orleans and the surrounding communities, is initiating a combined ... and medical care for unwanted animals in southern Louisiana. , Animal Rescue ...
Breaking Medicine News(10 mins):
... from exposure to medications, chemicals and other agentsSAN DIEGO, ... taking cold medication or using certain cleaning products can ... A new Web site ( ) ... latest information about the potential risks of exposure to ...
... restore sight, experts suggest , , THURSDAY, March 5 (HealthDay ... in two forms of childhood blindness has been identified ... of the link between the retinal gene SPATA7 and ... because it pinpoints a new retinal metabolic disease pathway ...
... 100 property and casualty insurers closed 2008 with net ... while the top 100 life insurers suffered unprecedented unrealized ... 2008 Top 100 Performance Monitor revealed a 67.7 percent ... industry,s top property and casualty insurers, from $48.8 billion ...
... Americas, Europe and Asia to Realize New Executive ... Tokyo Stock Exchange), a leading medical diagnostics ... announced executive leadership changes at Sysmex Corporate and ... Effective April 1, 2009, Kazuya Obe will ...
... stroke and heart disease are potential complications of type ... Americans. Now research from Tel Aviv University has found ... a risk factor accelerating cognitive decline and dementia. ... TAU,s Sackler School of Medicine, found that people with ...
... 2009 Many doctors don,t offer emergency contraception ... during emergency department visits because of misinformation about ... by The Children,s Hospital of Philadelphia. , ... reduce unintended pregnancy, the study,s authors said. ...
Cached Medicine News:
(Date:10/8/2015)...  The National Heart, Lung and Blood Institute ... Broad Institute of MIT and Harvard to provide ... well as data to support smaller pilots in ... for Precision Medicine (TOPMed) program and serves ... which will use whole genome sequencing to drive ...
(Date:10/8/2015)... 2015 ... "Natural Language Processing Market for Health ... (Rule-Based, Statistical, & Hybrid NLP Solutions), Region ... Africa, Latin America) - Global Forecast to ... --> ) has announced the ...
(Date:10/8/2015)... Oct. 08 2015 ... "Global API Market Outlook 2020" report ... has announced the addition of the "Global ... offering. --> Research and Markets ( ... "Global API Market Outlook 2020" report ...
Breaking Medicine Technology:
... Aug. 31, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... three upcoming investor conferences.  Dr. Mark A. Sirgo, President ... where he will focus on BDSI,s product pipeline, particularly ... which data from the pivotal Phase 3 efficacy study ...
... 2011 Elbit Imaging Ltd. (NASDAQ: EMITF) ... placed an Investor Relations Presentation relating to its Sources and ... "Investor Relations - Company Presentations -Analysis of Sources and Uses." ... Imaging Ltd. operates in the following principal fields of business: ...
Cached Medicine Technology:
Symbia T6, a True Point SPECT·CT system, combines a dual-detector variable angle gamma camera with a six slice CT scanner for advanced oncology, neurology, and cardiology applications....
... ACOM.PC turns every standard PC into ... internists, and cardiologists can use their ... access to image data thanks to ... 3 format and the compatible storage ...
... Soarian Cardiovascular Enterprise is a comprehensive ... care continuum from admission to follow-up. ... image acquisition, and diagnostic tools from ... provide a single, longitudinal clinical repository ...
... accurate lesion assessment plays a ... the appropriate stent size and ... (IC3D), a highly precise three-dimensional ... now able to quickly quantify ...
Medicine Products: